ArticleBrain and behavior2021
Hyperdense middle cerebral artery sign in large cerebral infarction.
Article in Brain and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Prognostic value of the hyperdense middle cerebral artery sign in patients undergoing mechanical thrombectomy.Medicine · 2026Article
- Hyperdense middle cerebral artery sign is a prognostic factor of favourable long-term outcomes of mechanical thrombectomy in acute ischaemic stroke.Neuroradiology · 2026Article
- Imaging-based machine learning to evaluate the severity of ischemic stroke in the middle cerebral artery territory.BMC medical imaging · 2025Article
- The prognostic significance of hyperdense middle cerebral artery sign in cardioembolic stroke patients undergoing mechanical thrombectomy.BMC neurology · 2025Article
- Analysis of Risk Factors for Hemorrhagic Transformation of Cerebral Infarction and Recurrence of Cerebral Infarction: A Retrospective Study on Cerebral Infarction Patients with or without Hemorrhagic Transformation.International journal of general medicine · 2025Article
- The value of radiomics-based hyperdense middle cerebral artery sign in predicting hemorrhagic transformation in acute ischemic stroke patients undergoing endovascular treatment.Frontiers in neurology · 2024Article
- Utility of the ASPECT Score for Predicting Intracranial Hemorrhage Following Intravenous Thrombolysis in Patients with Suspected MCA Infarction: Insights from the Northern Thai Stroke Registry.Journal of multidisciplinary healthcare · 2024Article
- New insight in massive cerebral infarction predictions after anterior circulation occlusion.Scientific reports · 2023Article
- Proximal hyperdense middle cerebral artery sign is associated with increased risk of asymptomatic hemorrhagic transformation after endovascular thrombectomy: a multicenter retrospective study.Journal of neurology · 2023Article
- Hyperdense middle cerebral artery sign predicts favorable outcome in patients undergoing mechanical thrombectomy.Journal of thrombosis and thrombolysis · 2023Article
- Prediction model of early biomarkers of massive cerebral infarction caused by anterior circulation occlusion: Establishment and evaluation.Frontiers in neurology · 2022Article
- Hyperdense middle cerebral artery sign in large cerebral infarction.Brain and behavior · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate if the hyperdense middle cerebral artery sign (HMCAS) is an imaging biomarker for hemorrhagic transformation (HT) and the functional outcome of patients with large cerebral infarctions without thrombolytic therapy. MATERIALS AND
methodsThe clinical and imaging data of 312 patients with large cerebral infarction without thrombolytic therapy were retrospectively analyzed. They were divided into patients who presented with HMCAS (n = 121) and those who did not (non-HMCAS[n = 168] patients), and the clinical data of the 2 groups were compared. This was a retrospective study.
resultsOf the 289 patients, 83(28.7%) developed HT. The incidence of atrial fibrillation, high homocysteine and admission NIHSS score at the time of admission was significantly higher in the HMCAS patients than in non-HMCAS patients (p < .05). The ASPECTS was significantly lower in HMCAS patients (t = -5.835, p < .001). The incidence of PH-2 and 3-month mRS score was also statistically significant higher in HMCAS patients (χ
conclusionsHMCAS in patients with a large cerebral infarction without thrombolytic therapy is an independent biomarker of HT. Length of HMCAS is also a marker of HT with lower ASPECTS in HMCAS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.